Sign in Subscribe
Cancer

Cancer Gene Therapy Market Set to Reach USD 17.35 Billion by 2032

Strategic Insights

— 2 min read

The global Cancer Gene Therapy Market is poised to experience significant growth, driven by factors such as increased cancer malignancy, research, and clinical trials on CAR-T and other gene therapies. The U.S. market is expected to reach USD 8.30 billion by 2032, growing at a CAGR of 19.90 percent over 2025-2032. The market growth is attributed to the increasing awareness of personalized medicine and therapies, as well as the development of gene-based therapies for treatment-resistant or recurrent cancers. Industrial investment and partnerships have also increased, leading to competition and new products entering the market.

Key Takeaways:

  • The global Cancer Gene Therapy Market was valued at USD 4.07 billion in 2024 and is expected to reach USD 17.35 billion by 2032, growing at a CAGR of 19.96 percent over 2025-2032.
  • The U.S. cancer gene therapy market was valued at USD 1.95 billion in 2024 and is expected to reach USD 8.30 billion by 2032, growing at a CAGR of 19.90 percent over 2025-2032.
  • The large B-cell lymphoma segment led the market share in 2024, driven by the successful launch and uptake of CAR-T cell therapies targeted against these indications.
  • The solid tumors, glioblastoma, pancreatic cancer, and other forms of malignancies segment is expected to grow at the highest CAGR during the forecast period.
  • The intravenous segment held the largest share of the cancer gene therapy market in 2024, with 91.25 percent, due to its traditional and prominent route of delivery for existing gene therapies.
  • The AAV segment is estimated to be the fastest-growing vector-based market during the forecast period, primarily due to breakthroughs in solid tumors and in vivo gene therapy.
  • The cancer research institute's segment dominated the cancer gene therapy market with a 74.5 percent market share in 2024, driven by their significant contributions to research in cancer treatments.
  • The Asia Pacific region is growing at a significant rate, following North America, due to a large patient population, high investment in genomics and biopharmaceuticals, and a high number of cancer cases.

Statistics:

  • Global Cancer Gene Therapy Market size: USD 4.07 billion in 2024, expected to reach USD 17.35 billion by 2032.
  • U.S. cancer gene therapy market size: USD 1.95 billion in 2024, expected to reach USD 8.30 billion by 2032.
  • CAGR growth rate: 19.96 percent over 2025-2032 for the global market, 19.90 percent over 2025-2032 for the U.S. market.
  • Large B-cell lymphoma market share: 54.26 percent in 2024.
  • Solid tumors, glioblastoma, pancreatic cancer, and other forms of malignancies segment growth rate: highest CAGR during the forecast period.
  • Intravenous segment market share: 91.25 percent in 2024.
  • AAV segment growth rate: fastest-growing vector-based market during the forecast period.
  • Cancer research institute's segment market share: 74.5 percent in 2024.
  • North America market share: 63.11 percent in 2024.
  • Asia Pacific market growth rate: significant rate, following North America.

Sources:

  • SNS Insider report cited in the Cancer Gene Therapy Market size, growth rate, and regional market shares.
  • SNS Insider report cited in the U.S. cancer gene therapy market size, growth rate, and regional market shares.
  • SNS Insider report cited in the segmentation analysis of the market by indication, route of administration, vector type, and end-user.

Read more